CROS

CROS

Warsaw, Poland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CROS CRO is a private, full-service contract research organization headquartered in Warsaw, Poland, operating in the clinical trial services sector. Founded in 2008, it has established itself as a regional player offering expertise across the entire drug development lifecycle, including complex First-in-Human trials. Its business model is service-based, generating revenue by managing and executing clinical trials for biopharmaceutical clients. The company's value proposition lies in its therapeutic focus and operational presence in Central and Eastern Europe, a region known for cost-effective patient recruitment.

OncologyCardiovascularInfectious Disease

Technology Platform

Integrated clinical trial service platform covering all phases (I-IV) and functions, from protocol design and regulatory submissions to monitoring, data management, and pharmacovigilance, with specialized expertise in First-in-Human and early-phase trials.

Opportunities

Growth is driven by the increasing outsourcing of clinical trials by biopharma and the attractiveness of the Central & Eastern European region for patient recruitment due to cost-effectiveness and access to treatment-naïve populations.
Specialization in complex early-phase trials and key therapeutic areas (oncology, CV, ID) allows CROS to target high-demand, value-added service segments.

Risk Factors

Key risks include intense competition from large global and other regional CROs, potential client concentration, and operational risks related to trial execution delays or quality issues.
The company also faces geographic concentration risk, being heavily reliant on the Polish and CEE markets, which are subject to local regulatory and economic shifts.

Competitive Landscape

CROS operates in the highly fragmented and competitive global CRO market. It competes directly with other regional CROs in Central and Eastern Europe and indirectly with large multinational CROs (e.g., IQVIA, ICON, Parexel) that have global scale and broad service offerings. Its competitive differentiation is based on deep local regulatory expertise, cost advantages, and personalized service for mid-sized and small biotech sponsors.